Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Parks Expands REMS Portfolio With Move To ODE II Deputy Slot

May 31 2013

• By Cathy Dombrowski

Related Content

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Dec 22 2008

Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking

Jan 07 2013

<em>Avandia</em> RECORD Study Re-Analysis To Get FDA Committee Scrutiny

Apr 12 2013

Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel

Jan 21 2013

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

Mar 29 2013

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment

Jul 16 2012

Anatomy Of The <i>Avandia</i> Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views

Oct 04 2010

FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics

Feb 18 2013

Arthritis Patient Classification To Be Key Issue In TNF Inhibitor Reviews

May 30 2013

Related Companies

GSK plc

Johnson & Johnson

Orexigen Therapeutics, Inc.

QRxPharma Limited

Purdue Pharma L.P.

Zogenix, Inc.

Additional Topics

Regulation Safety Risk Management BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window